Study of Plasma Biomarkers and Platelet Changes to Predict Outcomes in Cardiac Arrest Patients Undergoing Extracorporeal Cardiopulmonary Resuscitation ECPR

What this Trial Is About

Researchers are investigating plasma biomarkers and platelet morphology to better understand and predict outcomes in patients undergoing extracorporeal cardiopulmonary resuscitation ECPR for cardiac arrest. This observational study focuses on identifying protein and metabolic markers along with platelet changes that may help select cardiac arrest patients who could benefit most from ECPR and improve prognostic assessments. The study is led by Central China Fuwai Hospital of Zhengzhou University and addresses current limitations in objective biomarker use for ECPR eligibility and prognosis. The study observes cardiac arrest patients before and after receiving ECPR treatment, analyzing plasma proteomic and metabolomic profiles as well as platelet ultrastructural changes. Patients are categorized based on their recovery status after ECPR, including those who fully recover, those with organ dysfunction, and those who suffer brain death or death. There are no experimental treatments given as this is an observational study collecting data to find potential predictive markers. Participants will be monitored for up to 30 days after ECPR treatment, during which researchers will assess survival rates and neurological outcomes using measurements such as 30-day mortality, hospital survival, cerebral performance category scale, left ventricular ejection fraction, oxygenation ratio, and serum levels of bilirubin and creatinine. The study involves detailed blood sample analysis and clinical assessments to track the progression and outcomes following ECPR intervention.

Plasma Biomarkers and Platelet Morphology of Extracorporeal CardioPulmonary Resuscitation